There is a lot of work being done in the Fragile X research space! The NFXF is committed to keeping you up to date so you can consider available research opportunities for your family. You have the most questions about clinical trials, so we like to connect you directly with our Industry Partners for annual updates on their Fragile X programs.

This year representatives from Tetra Therapeutics, Zynerba Pharmaceuticals, and Allos Pharma will join us to share updates about their Fragile X programs. The webinar will be a series of short presentations from each Industry Partner on their Fragile X program with a Q & A after each presentation, moderated by Hilary Rosselot.

Registration is required: NFXF Webinar Series – 2023 Industry Update (fragilex.org)

We recommend reviewing the compilation of resources at the links below and come prepared with your questions. You may also submit your questions in advance when completing your registration.

• Zynerba: Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal
• Tetra: Clinical Trials: Phase 2B/3 Studies of BPN14770 in Fragile X syndrome
• Allos: Allos Pharma Inc. Receives FDA Guidance and Support for their Phase 3 Trial of Arbaclofen in Fragile X Syndrome

Each presenter will share a 10-minute update about their Fragile X program, followed by 5 minutes of Q&A. We will be hearing from:

• Chad Coberly, Tetra Therapeutics
• Stephen O’Quinn, Zynerba Pharmecuticals
• Randy Carpenter, Allos Pharma

We will do our best to answer everyone’s questions. If you have additional questions, feel free to email us at contact@fragilex.org.

The webinar will be recorded and available to all registrants.